Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksZotefoams Regulatory News (ZTF)

Share Price Information for Zotefoams (ZTF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 451.00
Bid: 452.00
Ask: 469.00
Change: -11.00 (-2.38%)
Spread: 17.00 (3.761%)
Open: 469.00
High: 469.00
Low: 451.00
Prev. Close: 462.00
ZTF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

13 Oct 2022 07:00

RNS Number : 7181C
Zotefoams PLC
13 October 2022
 

Zotefoams plc

("Zotefoams" or "Group")

 

Trading Update

Continued positive momentum through Q3 and full year expectations increased

 

13 October 2022 - Zotefoams, a world leader in cellular materials technology, today provides a trading update for the nine months ended 30 September 2022 ("year to date") and in respect of its financial year ending 31 December 2022.

Zotefoams is pleased to report a record third quarter sales performance, with Group revenues approximately 27% ahead of Q3 2021 which was its previous record third quarter. As a result, year to date Group revenue is approximately 24% ahead of the comparable period last year.

Current trading

Encouragingly, the Group continues to benefit from its broad customer diversification and has seen continued resilient demand across most of its end market segments. Both revenues and margins are also seeing an increasing benefit from pricing actions implemented earlier in the year, in response to cost inflation, as well as from a weaker Sterling exchange rate, primarily against the US dollar.

Reflecting this commercial backdrop, each of the Group's three business segments has delivered solid progress year to date with sales having increased by approximately:

27% in Polyolefin Foams with volumes increasing by 4%

20% in High-Performance Products (HPP) with growth of:

18% in footwear products

22% in aviation and other non-footwear HPP foams

39% in T-FIT® insulation products

11% in MuCell Extrusion, although these sales represented only around 2% of Group revenues, with the focus for the business being on the technical and commercial development of ReZorce® mono-material packaging solutions

Input cost inflation, other than energy prices, has seen some recent abatement, with commodity polymer prices declining from all-time high levels experienced late in the first half of this year. Wholesale energy prices remain volatile but, in the UK, which accounts for the majority of Group energy consumption, the short-term risk associated with energy pricing has been reduced due to Government pricing actions.

As described above, the Group has seen some benefit from Sterling weakness, albeit the impact of exchange rate movements on both sales and costs has been hedged in accordance with its hedging policy.

Good progress has been made on strategic initiatives, including the development of ReZorce, as well as the Group's wider ESG focus on reducing Scope 1 and 2 carbon emissions and launching foams with recycled content.

Outlook

Demand entering the final quarter remains encouraging and we have good visibility of confirmed orders for the remainder of 2022.

Based on its current sales forecasts and foreign exchange rates, and subject to there being no material disruption to the business, the Board now expects adjusted profit before income tax to be significantly ahead of market expectations*.

Cash generation also continues to be strong and so the better than anticipated earnings performance should contribute to an appreciable reduction in both net debt and leverage.

 

Commenting on the update David Stirling, Group CEO of Zotefoams, said: 

"I am delighted that Zotefoams is performing well in this volatile market environment which is a credit to our people, market positioning and strategy. Our exposure to a wide range of attractive markets has enabled us to deliver continued volume growth, which has been supported by the pricing actions taken earlier in the year.

We are mindful of the challenging backdrop but continue to see significant opportunity for the Group in both the short and longer term." 

 

* Current Company-compiled consensus expectations for adjusted profit before income tax and separately disclosed items, for the year ending 31 December 2022, is £9.3m.

 

 

- Ends -

 

Enquiries:

 

Zotefoams plc

+44 (0) 208 664 1600

David Stirling, Group CEO

Gary McGrath, Group CFO

 

IFC Advisory

+44 (0) 203 934 6630

Graham Herring

Tim Metcalfe

Zach Cohen

 

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc.

www.zotefoams.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGPGAUUUPPPUP
Date   Source Headline
12th Aug 20212:28 pmRNSDirector/PDMR Shareholding
10th Aug 20217:00 amRNSInterim Results
19th Jul 20219:26 amRNSNotice of Results
13th Jul 20211:59 pmRNSDirector/PDMR Shareholding
14th Jun 20213:06 pmRNSDirector/PDMR Shareholding
14th Jun 202111:35 amRNSDirector/PDMR Shareholding
10th Jun 20214:41 pmRNSDirector/PDMR Shareholding
9th Jun 20213:48 pmRNSDirector/PDMR Shareholding
2nd Jun 20213:49 pmRNSHolding(s) in Company
26th May 202112:08 pmRNSResult of AGM
26th May 20217:00 amRNSTrading Update
12th May 20213:44 pmRNSDirector/PDMR Shareholding
28th Apr 20212:05 pmRNSDirector/PDMR Shareholding
26th Apr 20213:16 pmRNS2020 Annual Report, Notice of the 2021 AGM
13th Apr 20212:06 pmRNSDirector/PDMR Shareholding
12th Apr 20214:09 pmRNSDirector/PDMR Shareholding
25th Mar 20211:26 pmRNSDirector/PDMR Shareholding
23rd Mar 20213:19 pmRNSCorrection: Preliminary Results
23rd Mar 20217:00 amRNSPreliminary Results
12th Mar 20212:53 pmRNSDirector/PDMR Shareholding
10th Mar 20211:12 pmRNSHolding(s) in Company
9th Mar 20213:13 pmRNSHolding(s) in Company
9th Mar 20213:05 pmRNSHolding(s) in Company
9th Mar 20211:55 pmRNSHolding(s) in Company
8th Mar 20213:04 pmRNSResult of secondary placing in Zotefoams plc
8th Mar 202112:00 pmRNSProposed secondary placing in Zotefoams plc
8th Mar 20217:00 amRNSNotice of results and investors presentation
5th Mar 20214:36 pmRNSPrice Monitoring Extension
23rd Feb 20217:00 amRNSProduction starts at new £23m plant in Poland
15th Feb 20217:00 amRNSPolish factory virtual tour and investor Q&A
12th Feb 20214:20 pmRNSDirector/PDMR Shareholding - Replacement
12th Feb 20213:54 pmRNSDirector/PDMR Shareholding
12th Feb 20213:38 pmRNSDirector/PDMR Shareholding
8th Feb 20214:41 pmRNSSecond Price Monitoring Extn
8th Feb 20214:35 pmRNSPrice Monitoring Extension
21st Jan 20217:00 amRNSOperational and Trading Update
12th Jan 20213:50 pmRNSDirector/PDMR Shareholding
14th Dec 20204:19 pmRNSDirector/PDMR Shareholding
12th Nov 20203:40 pmRNSDirector/PDMR Shareholding
5th Nov 20207:00 amRNSOperational and Trading Update
22nd Oct 202010:36 amRNSDirector/PDMR Shareholding
14th Oct 20207:00 amRNSDirector/PDMR Shareholding
9th Oct 20207:00 amRNSDirector/PDMR Shareholding
7th Oct 20207:00 amRNSExternal Auditor Appointment
1st Oct 20204:13 pmRNSDirector/PDMR Shareholding
16th Sep 20204:29 pmRNSDirector/PDMR Shareholding
11th Sep 20204:41 pmRNSSecond Price Monitoring Extn
11th Sep 20204:35 pmRNSPrice Monitoring Extension
9th Sep 20205:51 pmRNSHolding(s) in Company
1st Sep 20204:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.